Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
UPTIDER is a prospective, interventional, non-Investigational Medicinal Product (non-IMP), non-commercial, single centre post-mortem tissue donation program for metastatic breast cancer patients or patients with a germline pathogenic variant with a moderate to high lifetime risk of breast cancer and at least one malignancy at time of death. The overarching objective of UPTIDER is (i) to unravel metastatic breast cancer evolution, biology, heterogeneity and treatment resistance and (ii) to assess pathogenicity and tumour biology in hereditary cancer syndromes with a high lifetime risk of breast cancer; both through extensive post-mortem multi-level and multi-region sample analysis.
Description: Should be equal to or above 50%
Measure: Percentage of patients consenting to participate in the pilot phase Time: BaselineDescription: Should be equal to or less than 12h
Measure: Median time elapsed between moment of death and start of the autopsy Time: During autopsyDescription: Should be equal to or less than 8h
Measure: Median time elapsed between collection of first and last sample Time: During autopsyDescription: Should be equal to or more than 75%
Measure: Percentage of metastatic organs sampled Time: During autopsyDescription: A260/A280 ratio
Measure: Percentage of samples with sufficient quality of DNA extracted Time: During autopsyDescription: RNA integrity number (RIN)
Measure: Percentage of samples with sufficient quality of RNA extracted Time: During autopsyDescription: Standard histopathological review
Measure: Concordance between TILs and clinical response to treatment Time: During autopsyDescription: RNA sequencing
Measure: Rate of T cell exhaustion Time: During autopsyDescription: Whole exome sequencing
Measure: Number of mutations in each tumor lesion Time: During autopsyDescription: Whole exome sequencing
Measure: Type of mutations in each tumor lesion Time: During autopsyDescription: Standard histopathological review
Measure: Percentage of Tumour Infiltrating Lymphocytes (TILs) Time: During autopsyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports